ST 2825
Based on 71 publication(s) in Google Scholar
ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activity.
For research use only. We do not sell to patients.
- Purity: 99.92%
- CAS No.: 894787-30-5
- Formula: C27H28Cl2N4O5S
- Molecular Weight:591.51
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) ST 2825
More- Gut. 2018 Nov;67(11):2035-2044. [Abstract]
- Cancer Res. 2019 Mar 1;79(5):918-927. [Abstract]
- ACS Nano. 2015 Oct 27;9(10):10498-515. [Abstract]
- Nat Commun. 2023 Jan 17;14(1):143. [Abstract]
- Theranostics. 2020 Sep 15;10(25):11479-11496. [Abstract]
- Biomaterials. 2020 May;241:119852. [Abstract]
- J Infection. 2019 Sep;79(3):262-276. [Abstract]
- J Immunother Cancer. 2024 Jun 26;12(6):e009082. [Abstract]
- J Immunother Cancer. 2021 Dec;9(12):e003339. [Abstract]
- J Neuroinflammation. 2018 Mar 19;15(1):87. [Abstract]
- Cell Death Dis. 2022 Apr 28;13(4):411. [Abstract]
- Cell Death Dis. 2021 May 12;12(5):477. [Abstract]
- J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):677-695. [Abstract]
- Int J Biol Macromol. 2021 Jul 31:183:79-89. [Abstract]
- Int J Biol Macromol. 2018 May:111:813-821. [Abstract]
- Br J Pharmacol. 2015 Jun;172(12):3159-76. [Abstract]
- Emerg Microbes Infect. Jan-Feb 2021;23(1):104765. [Abstract]
- Cell Rep. 2019 Nov 26;29(9):2718-2730.e6. [Abstract]
- Acta Neuropathol Commun. 2020 Aug 13;8(1):135. [Abstract]
- J Invest Dermatol. 2019 Dec;139(12):2488-2496.e4. [Abstract]
- Inflamm Res. 2023 May;72(5):901-913. [Abstract]
- Inflammopharmacology. 2019 Dec;27(6):1143-1153. [Abstract]
- J Pathol. 2022 Apr;256(4):414-426. [Abstract]
- PLoS Pathog. 2025 Mar 11;21(3):e1012985. [Abstract]
- Cell Oncol (Dordr). 2024 Dec;47(6):2147-2162. [Abstract]
- Int Immunopharmacol. 2023 Apr:117:109890. [Abstract]
- Int Immunopharmacol. 2018 Nov:64:33-41. [Abstract]
- Molecules. 2022 May 6;27(9):2990. [Abstract]
- Molecules. 2018 Oct 16;23(10). pii: E2658. [Abstract]
- FEBS J. 2025 Nov 27. [Abstract]
- Mediators Inflamm. 2021 Dec 21:2021:9993971. [Abstract]
- FASEB J. 2021 Oct;35(10):e21820. [Abstract]
- Exp Neurol. 2017 Sep:295:23-35. [Abstract]
- J Inflamm. 2022 Dec 30;19(1):28. [Abstract]
- J Cell Physiol. 2019 May;234(5):7645-7658. [Abstract]
- Oncol Rep. 2023 Aug;50(2):148. [Abstract]
- Oncol Rep. 2019 Nov;42(5):1755-1766. [Abstract]
- Sci Rep. 2017 Nov 17;7(1):15797. [Abstract]
- Sci Rep. 2017 Mar 17;7:44822. [Abstract]
- Eur J Immunol. 2020 Sep;50(9):1350-1361. [Abstract]
- Bone. 2022 Apr:157:116324. [Abstract]
- Food Chem Toxicol. 2022 Oct:168:113400. [Abstract]
- Mol Med Rep. 2015 Jul;12(1):895-904. [Abstract]
- PLoS Negl Trop Dis. 2018 Dec 27;12(12):e0007000. [Abstract]
- Front Oncol. 2020 Sep 18:10:1780. [Abstract]
- Mycopathologia. 2021 Jun;186(3):341-354. [Abstract]
- Vet Microbiol. 2019 Aug:235:53-62. [Abstract]
- PLoS One. 2026 Mar 6;21(3):e0344474. [Abstract]
- Brain Res. 2016 Jul 15:1643:130-9. [Abstract]
- PLoS One. 2014 Jul 18;9(7):e100985. [Abstract]
- J Biomater Appl. 2023 Jul;38(1):146-156. [Abstract]
- Theriogenology. 2020 Aug;152:129-138. [Abstract]
- Theriogenology. 2018 Oct 1:119:80-90. [Abstract]
- Biochem Biophys Rep. 2024 Mar 5:38:101681. [Abstract]
- Oncol Lett. 2018 Oct;16(4):4929-4936. [Abstract]
- Oncol Lett. 2018 Jun;15(6):9647-9654. [Abstract]
- Neurosci Lett. 2022 Jan 18:768:136374. [Abstract]
- Anticancer Res. 2017 Nov;37(11):6203-6209. [Abstract]
- Dev Dyn. 2022 Jun;251(6):988-1003. [Abstract]
- Eur J Inflamm. May 16, 2022.
- Genet Mol Res. 2016 Mar 4;15(1):15016826. [Abstract]
- bioRxiv. 2026 Apr 1:2026.03.31.715684. [Abstract]
- Patent. US20240197876A1.
- bioRxiv. 2024 Jan 20.
- Research Square Preprint. 2021 Nov.
- Technische Universitat Dresden. 2021 Oct 4.
- Research Square Preprint. 2020 Jun.
- bioRxiv. 2020 Apr.
- Oxid Med Cell Longev. 2018 Jun 26:2018:2917981. [Abstract]
- Indiana University. 2018 May.
- Journal of China Medical University. 2015 Jun; 44(6): 562-564.
-
WB
-
WB
-
WB
-
WB
-
WB
Biological Activity
MyD88[1]
ST2825 blocks IL-1R/TLR signaling by interfering with MyD88 homodimerization. ST2825 inhibits this interaction in a concentration-dependent manner with ~40% inhibition of dimerization at 5 μM ST2825 and 80% inhibition at 10 μM ST2825[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 894787-30-5
-
Appearance Solid
-
Molecular Weight 591.51
-
Formula C27H28Cl2N4O5S
-
Color White to off-white
-
SMILES
O=C(N([C@H]1C(N)=O)[C@@](SCC1)([H])C2)[C@]2(CCC3)N3C(CC4=CC=C(C=C4)NC(COC(C(Cl)=C5)=CC=C5Cl)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (71)
-
Journal Impact Factor
-
Most Recent
-
Gut
Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection. [Abstract]2018 Nov;67(11):2035-2044. PMID: 28899983 -
Cancer Res
Acetylation of CCAR2 Establishes a BET/BRD9 Acetyl Switch in Response to Combined Deacetylase and Bromodomain Inhibition. [Abstract]2019 Mar 1;79(5):918-927. PMID: 30643017 -
ACS Nano
Crucial Role of Lateral Size for Graphene Oxide in Activating Macrophages and Stimulating Pro-inflammatory Responses in Cells and Animals. [Abstract]2015 Oct 27;9(10):10498-515. PMID: 26389709 -
Nat Commun
In vivo induction of activin A-producing alveolar macrophages supports the progression of lung cell carcinoma. [Abstract]2023 Jan 17;14(1):143. PMID: 36650150 -
Theranostics
Redox DAPK1 destabilizes Pellino1 to govern inflammation-coupling tubular damage during septic AKI. [Abstract]2020 Sep 15;10(25):11479-11496. PMID: 33052227 -
Biomaterials
Cholesterol-modified DP7 enhances the effect of individualized cancer immunotherapy based on neoantigens. [Abstract]2020 May;241:119852. PMID: 32120313 -
J Infection
Interferon regulatory factor 1 eliminates mycobacteria by suppressing p70 S6 kinase via mechanistic target of rapamycin signaling. [Abstract]2019 Sep;79(3):262-276. PMID: 31226272 -
J Immunother Cancer
Tumor cell-released autophagosomes (TRAPs) induce PD-L1-decorated NETs that suppress T-cell function to promote breast cancer pulmonary metastasis. [Abstract]2024 Jun 26;12(6):e009082. PMID: 38926151 -
J Immunother Cancer
Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function. [Abstract]2021 Dec;9(12):e003339. PMID: 34937742 -
J Neuroinflammation
Peroxiredoxin 2 activates microglia by interacting with Toll-like receptor 4 after subarachnoid hemorrhage. [Abstract]2018 Mar 19;15(1):87. PMID: 29554978 -
Cell Death Dis
MyD88 in hepatic stellate cells enhances liver fibrosis via promoting macrophage M1 polarization. [Abstract]2022 Apr 28;13(4):411. PMID: 35484116 -
Cell Death Dis
2021 May 12;12(5):477. PMID: 33980825 -
J Cachexia Sarcopenia Muscle
MyD88 deficiency ameliorates weight loss caused by intestinal oxidative injury in an autophagy-dependent mechanism. [Abstract]2022 Feb;13(1):677-695. PMID: 34811946 -
Int J Biol Macromol
Immunomodulatory effect of intracellular polysaccharide from mycelia of Agaricus bitorquis (QuéL.) Sacc. Chaidam by TLR4-mediated MyD88 dependent signaling pathway. [Abstract]2021 Jul 31:183:79-89. PMID: 33901556 -
Int J Biol Macromol
Polygonatum sibiricum polysaccharides play anti-cancer effect through TLR4-MAPK/NF-κB signaling pathways. [Abstract]2018 May:111:813-821. PMID: 29343453 -
Br J Pharmacol
Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension. [Abstract]2015 Jun;172(12):3159-76. PMID: 25712370 -
Emerg Microbes Infect
TREM-1 enhances Mycobacterium tuberculosis-induced inflammatory responses in macrophages. [Abstract]Jan-Feb 2021;23(1):104765. PMID: 33049389 -
Cell Rep
IRF-7 Is a Critical Regulator of Type 2 Innate Lymphoid Cells in Allergic Airway Inflammation. [Abstract]2019 Nov 26;29(9):2718-2730.e6. PMID: 31775040 -
Acta Neuropathol Commun
Lipid-specific IgMs induce antiviral responses in the CNS: implications for progressive multifocal leukoencephalopathy in multiple sclerosis. [Abstract]2020 Aug 13;8(1):135. PMID: 32792006 -
J Invest Dermatol
miR-146a Inhibits Biofilm-Derived Cutibacterium acnes-Induced Inflammatory Reactions in Human Keratinocytes. [Abstract]2019 Dec;139(12):2488-2496.e4. PMID: 31194941 -
Inflamm Res
Increased sympathetic outflow induced by emotional stress aggravates myocardial ischemia-reperfusion injury via activation of TLR7/MyD88/IRF5 signaling pathway. [Abstract]2023 May;72(5):901-913. PMID: 36933018 -
Inflammopharmacology
Neuroprotective and anti-inflammatory effects of isoliquiritigenin in kainic acid-induced epileptic rats via the TLR4/MYD88 signaling pathway. [Abstract]2019 Dec;27(6):1143-1153. PMID: 31037573 -
J Pathol
MyD88 in myofibroblasts regulates aerobic glycolysis-driven hepatocarcinogenesis via ERK-dependent PKM2 nuclear relocalization and activation. [Abstract]2022 Apr;256(4):414-426. PMID: 34927243 -
PLoS Pathog
Enhancing MyD88 oligomerization is one important mechanism by which IBDV VP2 induces inflammatory response. [Abstract]2025 Mar 11;21(3):e1012985. PMID: 40067802 -
Cell Oncol (Dordr)
Tumour cell-released autophagosomes promote lung metastasis by upregulating PD-L1 expression in pulmonary vascular endothelial cells in breast cancer. [Abstract]2024 Dec;47(6):2147-2162. PMID: 39373859 -
Int Immunopharmacol
Effects of Aire on perforin expression in BMDCs via TLR7/8 and its therapeutic effect on type 1 diabetes. [Abstract]2023 Apr:117:109890. PMID: 36805202 -
Int Immunopharmacol
The activation of Toll-like receptor 4 reverses tumor differentiation in human glioma U251 cells via Notch pathway. [Abstract]2018 Nov:64:33-41. PMID: 30145468
ST 2825 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2018 Nov:64:33-41. [Abstract]
Western blot analysis of the protein levels of the phosphorylated NF-κB P65 levels, and the phosphorylated ERK levels in U251 cells, pre-treated with the indicated concentrations of ST2825 (ST) for 24 h, and re-treated with 1 μg/mL LPS for 1 h.
-
Molecules
ST2825, a Small Molecule Inhibitor of MyD88, Suppresses NF-κB Activation and the ROS/NLRP3/Cleaved Caspase-1 Signaling Pathway to Attenuate Lipopolysaccharide-Stimulated Neuroinflammation. [Abstract]2022 May 6;27(9):2990. PMID: 35566338 -
Molecules
1,4- β-d-Glucomannan from Dendrobium officinale Activates NF- к B via TLR4 to Regulate the Immune Response. [Abstract]2018 Oct 16;23(10). pii: E2658. PMID: 30332800 -
FEBS J
LC3-positive extracellular vesicles released from tumor cells promote lung metastasis of breast cancer by inducing vascular permeability. [Abstract]2025 Nov 27. PMID: 41307630 -
Mediators Inflamm
Extracellular HMGB1 Induced Glomerular Endothelial Cell Injury via TLR4/MyD88 Signaling Pathway in Lupus Nephritis. [Abstract]2021 Dec 21:2021:9993971. PMID: 34970076 -
FASEB J
Candida albicans-induced leukotriene biosynthesis in neutrophils is restricted to the hyphal morphology. [Abstract]2021 Oct;35(10):e21820. PMID: 34569657 -
Exp Neurol
Myeloid differentiation factor 88 is up-regulated in epileptic brain and contributes to experimental seizures in rats. [Abstract]2017 Sep:295:23-35. PMID: 28529112
ST 2825 purchased from MedChemExpress. Usage Cited in: Exp Neurol. 2017 Sep:295:23-35. [Abstract]
Western blotting analysis of the Tyr1472-phosphorylation of the NR2B subunit in the hippocampus of experimental rats under the various treatment conditions. ST2825 (10 μg in 2 μL) is injected. Representative Western blotting bands corresponding to the specific proteins and the various pharmacological treatments.
-
J Inflamm
Bystander effect of SARS-CoV-2 spike protein on human monocytic THP-1 cell activation and initiation of prothrombogenic stimulus representing severe COVID-19. [Abstract]2022 Dec 30;19(1):28. PMID: 36585712 -
J Cell Physiol
2019 May;234(5):7645-7658. PMID: 30414292
ST 2825 purchased from MedChemExpress. Usage Cited in: J Cell Physiol. 2019 May;234(5):7645-7658. [Abstract]
Western blot analysis shows the level of NFATc1 in cells stimulated with RANKL in the presence or absence of ST 2825.
-
Oncol Rep
The MyD88 inhibitor, ST2825, induces cell cycle arrest and apoptosis by suppressing the activation of the NF‑κB/AKT1/p21 pathway in pancreatic cancer. [Abstract]2023 Aug;50(2):148. PMID: 37326109 -
Oncol Rep
Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825. [Abstract]2019 Nov;42(5):1755-1766. PMID: 31432184 -
Sci Rep
Inhibition of myeloid differentiation primary response protein 88 provides neuroprotection in early brain injury following experimental subarachnoid hemorrhage. [Abstract]2017 Nov 17;7(1):15797. PMID: 29150630
ST 2825 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2017 Nov 17;7(1):15797. [Abstract]
Representative Western blot to show the level of MyD88 protein. The upper panel shows representative protein levels of MyD88. Tubulin is detected as a loading control. The bottom panel shows quantitative data of MyD88.
-
Sci Rep
Astragalus polysaccharides exerts immunomodulatory effects via TLR4-mediated MyD88-dependent signaling pathway in vitro and in vivo. [Abstract]2017 Mar 17;7:44822. PMID: 28303957 -
Eur J Immunol
Neutralization of IL-10 produced by B cells promotes protective immunity during persistent HCV infection in humanized mice. [Abstract]2020 Sep;50(9):1350-1361. PMID: 32339264 -
Bone
Modulating the systemic and local adaptive immune response after fracture improves bone regeneration during aging. [Abstract]2022 Apr:157:116324. PMID: 34998981 -
Food Chem Toxicol
Apigenin and apigenin-7, 4'-O-dioctanoate protect against acrolein-aggravated inflammation via inhibiting the activation of NLRP3 inflammasome and HMGB1/MYD88/NF-κB signaling pathway in Human umbilical vein endothelial cells (HUVEC). [Abstract]2022 Oct:168:113400. PMID: 36055550 -
Mol Med Rep
Roles of lipoxin A4 receptor activation and anti-interleukin-1β antibody on the toll-like receptor 2/mycloid differentiation factor 88/nuclear factor-κB pathway in airway inflammation induced by ovalbumin. [Abstract]2015 Jul;12(1):895-904. PMID: 25760938
ST 2825 purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2015 Jul;12(1):895-904. [Abstract]
The degradation of IκBα and nuclear translocation of p65 induced by IL-1β are also dramatically blocked by pretreatment of the cells with TLR2Ab, ST2825 and TPCA-1. The cultured leukocytes are obtained from a normal control mouse and stimulated with IL-1β (10 ng/ml) for 1 h with or without pre-treatment of BML-111 (1 mM) for 30 min, BOC1 (100 μM) for 30 min, TLR2Ab (1 μg/mL) for 1 h, goat IgG (1 μg/mL) for 1 h, ST2825 (20 μM) for 1 h or TPCA-1 (10 μM) for 1 h. The western blot is representative
-
PLoS Negl Trop Dis
Toll-like receptor-2 regulates macrophage polarization induced by excretory-secretory antigens from Schistosoma japonicum eggs and promotes liver pathology in murine schistosomiasis. [Abstract]2018 Dec 27;12(12):e0007000. PMID: 30589840 -
Front Oncol
Myeloid Differentiation Primary Response 88-Cyclin D1 Signaling in Breast Cancer Cells Regulates Toll-Like Receptor 3-Mediated Cell Proliferation. [Abstract]2020 Sep 18:10:1780. PMID: 33072559 -
Mycopathologia
MiR-146a Negatively Regulates Aspergillus fumigatus-Induced TNF-α and IL-6 Secretion in THP-1 Macrophages. [Abstract]2021 Jun;186(3):341-354. PMID: 34089172 -
Vet Microbiol
Mycoplasma hyopneumoniae Mhp597 is a cytotoxicity, inflammation and immunosuppression associated nuclease. [Abstract]2019 Aug:235:53-62. PMID: 31282379 -
PLoS One
TLR9/MyD88/NF-κB signaling mediates mental stress-induced exacerbation of psoriasis through immune dysregulation in a mouse model. [Abstract]2026 Mar 6;21(3):e0344474. PMID: 41790734 -
Brain Res
Inhibition of myeloid differentiation factor 88(MyD88) by ST2825 provides neuroprotection after experimental traumatic brain injury in mice. [Abstract]2016 Jul 15:1643:130-9. PMID: 27155455
ST 2825 purchased from MedChemExpress. Usage Cited in: Brain Res. 2016 Jul 15:1643:130-9. [Abstract]
Effect of ST2825 treatment on the expression of MyD88 at 24h after TBI. Levels of MyD88 are significantly increased at 24 h after TBI. ST2825 (20 μg/μL) treatment reduces the levels of MyD88 at 24 h post TBI. No difference is detected between the TBI group and TBI+vehicle group.
-
PLoS One
7-Ketocholesterol-induced inflammation signals mostly through the TLR4 receptor both in vitro and in vivo. [Abstract]2014 Jul 18;9(7):e100985. PMID: 25036103 -
J Biomater Appl
Stromal vascular fraction gel promoted wound healing and peripheral nerve repair in diabetic rats via TLRs/MyD88/NF-κB signaling pathway. [Abstract]2023 Jul;38(1):146-156. PMID: 37341245 -
Theriogenology
TLR2/4 promotes PGE2 production to increase tissue damage in Escherichia coli-infected bovine endometrial explants via MyD88/p38 MAPK pathway. [Abstract]2020 Aug;152:129-138. PMID: 32408026 -
Theriogenology
Antimicrobial peptide expression in swine granulosa cells in response to lipopolysaccharide. [Abstract]2018 Oct 1:119:80-90. PMID: 29982140 -
Biochem Biophys Rep
ST2825, independent of MyD88, induces reactive oxygen species-dependent apoptosis in multiple myeloma cells. [Abstract]2024 Mar 5:38:101681. PMID: 38455592 -
Oncol Lett
An analysis of the expression and function of myeloid differentiation factor 88 in human osteosarcoma. [Abstract]2018 Oct;16(4):4929-4936. PMID: 30250559
ST 2825 purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 Oct;16(4):4929-4936. [Abstract]
Western blot analysis of p65 and cleaved caspase 3 in high dose ST2825 treated cells. High dose ST2825 significantly inhibits nuclear p65 in osteosarcoma cells, and significantly increases cleaved caspase 3 protein expression.
ST 2825 purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 Oct;16(4):4929-4936. [Abstract]
Western blot analysis of cyclin D1 and MMP 9 in high dose ST2825 treated cells. High dose ST2825 significantly inhibits cyclin D1 expression in osteosarcoma cells, and significantly increases MMP9 protein expression.
-
Oncol Lett
Activation of the TLR4/MyD88 signaling pathway contributes to the development of human hepatocellular carcinoma via upregulation of IL-23 and IL-17A. [Abstract]2018 Jun;15(6):9647-9654. PMID: 29928340 -
Neurosci Lett
Inhibiting RGS1 attenuates secondary inflammation response and tissue degradation via the TLR/TRIF/NF-κB pathway in macrophage post spinal cord injury. [Abstract]2022 Jan 18:768:136374. PMID: 34852285 -
Anticancer Res
2017 Nov;37(11):6203-6209. PMID: 29061802
ST 2825 purchased from MedChemExpress. Usage Cited in: Anticancer Res. 2017 Nov;37(11):6203-6209. [Abstract]
Effect of ST2825 on the expression of myeloid differentiation primary response gene 88 (MYD88) and nuclear factor kappa B (NF-ĸB) signaling proteins. Cells are cultured with 100 μM ST2825 for 6 h and analysed for protein expression by immunoblotting. DMSO is used as a vehicle control and α-tubulin as a loading control.
-
Dev Dyn
2022 Jun;251(6):988-1003. PMID: 33797128 -
-
Genet Mol Res
Effect of ST2825 on the proliferation and apoptosis of human hepatocellular carcinoma cells. [Abstract]2016 Mar 4;15(1):15016826. PMID: 26985932
ST 2825 purchased from MedChemExpress. Usage Cited in: Genet Mol Res. 2016 Mar 4;15(1):15016826. [Abstract]
Effect of ST2825 on IκB, cyclin D1, cleaved caspase-3, and bcl-2 expression in HepG-2 cells as determined by western blot analysis (lane 1, blank; lane 2, control; and lane 3, high-dose ST2825). Compared with the control, 24 h of ST2825 treatment significantly inhibits cyclin D1 and bcl-2 expression (P>0.05), but 24-h treatment with ST2825 significantly increases cleaved caspase-3 expression (P<0.05) in the high-dose group.
-
bioRxiv
Efficient Generation of Functional TCRαβ+ Cytotoxic T Cells from hiPSCs via Small-Molecule Modulation. [Abstract]2026 Apr 1:2026.03.31.715684. PMID: 41959015 -
-
-
-
-
-
-
Oxid Med Cell Longev
2018 Jun 26:2018:2917981. PMID: 30046373 -
-
Solvent & Solubility
DMSO : 100 mg/mL (169.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.23 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
HeLa cells are seeded at 105 cells/mL in a 96-well tissue-culture plate. After incubating overnight, the medium is discarded, and the cells are added with tissue culture medium, 10% FBS, containing ST2825 at concentrations ranging from 0.1 to 10 μM and DMSO at 0.1% final concentration. The cells are incubated for 6 and 18 h and then added with the yellow XTT (0.3 mg/mL) for further 2 h of incubation. At the end of the incubation periods, reactions are quantified by using a Sirio S Seac microplate reader[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[1]
Mice (female C57Bl/6) are divided into experimental groups of 15 mice. They are injected i.p. with saline (control animals) or recombinant murine IL-1β (20 μg/kg). A time-course analysis of IL-6 production established that the peak of cytokine is reached 2 h after IL-1β injection. ST2825, administered orally as 0.5% suspension in carboxymethylcellulose (CMC) or CMC alone, is supplied to the experimental mice groups. Two hours after IL-1β injection, the animals are killed, and sera are collected to assay IL-6 levels. Mice, which are treated orally with 100 and 200 mg/kg ST2825, shows lower levels of IL-6 versus CMC-treated mice.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (289 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Loiarro M, et al. Pivotal advance: inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol. 2007 Oct;82(4):801-10. [Content Brief]
[2]. Fantò N, et al. Design, Synthesis, and In Vitro Activity of Peptidomimetic Inhibitors of Myeloid Differentiation Factor 88. J Med Chem. 2008 Mar 13;51(5):1189-202. [Content Brief]
[3]. Van Tassell BW, et al. Pharmacologic Inhibition of Myeloid Differentiation Factor 88 (MyD88) Prevents Left Ventricular Dilation and Hypertrophy After Experimental Acute Myocardial Infarction in the Mouse. J Cardiovasc Pharmacol. 2010 Apr;55(4):385-90. [Content Brief]
[4]. Zhang HS, et al. Inhibition of myeloid differentiation factor 88(MyD88) by ST2825 provides neuroprotection after experimental traumatic brain injury in mice. Brain Res. 2016 Jul 15;1643:130-9. [Content Brief]
[5]. Wang N, et al. Myeloid differentiation factor 88 is up-regulated in epileptic brain and contributes to experimental seizures in rats. Exp Neurol. 2017 Sep;295:23-35. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6906 mL | 8.4529 mL | 16.9059 mL | 42.2647 mL |
| 5 mM | 0.3381 mL | 1.6906 mL | 3.3812 mL | 8.4529 mL | |
| 10 mM | 0.1691 mL | 0.8453 mL | 1.6906 mL | 4.2265 mL | |
| 15 mM | 0.1127 mL | 0.5635 mL | 1.1271 mL | 2.8176 mL | |
| 20 mM | 0.0845 mL | 0.4226 mL | 0.8453 mL | 2.1132 mL | |
| 25 mM | 0.0676 mL | 0.3381 mL | 0.6762 mL | 1.6906 mL | |
| 30 mM | 0.0564 mL | 0.2818 mL | 0.5635 mL | 1.4088 mL | |
| 40 mM | 0.0423 mL | 0.2113 mL | 0.4226 mL | 1.0566 mL | |
| 50 mM | 0.0338 mL | 0.1691 mL | 0.3381 mL | 0.8453 mL | |
| 60 mM | 0.0282 mL | 0.1409 mL | 0.2818 mL | 0.7044 mL | |
| 80 mM | 0.0211 mL | 0.1057 mL | 0.2113 mL | 0.5283 mL | |
| 100 mM | 0.0169 mL | 0.0845 mL | 0.1691 mL | 0.4226 mL |